123 related articles for article (PubMed ID: 324955)
1. Present status of CMF adjuvant therapy in operable breast cancer.
Bonadonna G
Int J Radiat Oncol Biol Phys; 1977; 2(3-4):237-40. PubMed ID: 324955
[No Abstract] [Full Text] [Related]
2. The case for adjuvant CMF chemotherapy in breast cancer. Has it been made?
Levitt SH; Potish RA
Cancer Clin Trials; 1981; 4(4):363-9. PubMed ID: 7032731
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant combination chemotherapy in primary mammary carcinoma: the CMF program.
Rossi A; Bonadonna G; Valagussa P; Veronesi U
Recent Results Cancer Res; 1977; (62):134-42. PubMed ID: 341246
[No Abstract] [Full Text] [Related]
4. The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance.
Bonadonna G; Rossi A; Valagussa P; Banfi A; Veronesi U
Cancer; 1977 Jun; 39(6 Suppl):2904-15. PubMed ID: 326384
[TBL] [Abstract][Full Text] [Related]
5. CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial.
Mouridsen HT; Palshof T; Engelsman E; Sylvester R
Eur J Cancer (1965); 1980; Suppl 1():119-23. PubMed ID: 7032921
[No Abstract] [Full Text] [Related]
6. Multimodal therapy with CMF in resectable breast cancer with positive axillary nodes: the Milan Institute experience.
Bonadonna G; Valagussa P; Rossi A; Tancini G; Brambilla C; Marchini S; Veronesi U
Recent Results Cancer Res; 1982; 80():149-56. PubMed ID: 7036277
[No Abstract] [Full Text] [Related]
7. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.
Brincker H; Rose C; Rank F; Mouridsen HT; Jakobsen A; Dombernowsky P; Panduro J; Andersen KW
J Clin Oncol; 1987 Nov; 5(11):1771-8. PubMed ID: 3316514
[TBL] [Abstract][Full Text] [Related]
8. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
Jonat W; Kaufmann M; Sauerbrei W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; de Matteis A; Stewart A; Eiermann W; Szakolczai I; Palmer M; Schumacher M; Geberth M; Lisboa B;
J Clin Oncol; 2002 Dec; 20(24):4628-35. PubMed ID: 12488406
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant combination chemotherapy with CMF in primary mammary carcinoma.
Veronesi U; Rossi A; Bonadonna G
World J Surg; 1977 May; 1(3):337-40. PubMed ID: 883333
[No Abstract] [Full Text] [Related]
10. Multimodal treatment in operable breast cancer: five-year results of the CMF programme.
Rossi A; Bonadonna G; Valagussa P; Veronesi U
Br Med J (Clin Res Ed); 1981 May; 282(6274):1427-31. PubMed ID: 6784849
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant hormono-chemotherapy in operable breast cancer.
Wilson R; Hanham IW; Mair G; Drake SR; Derry CD; McKenzie C; Stoll BA; Boesen E; Skeggs DB; Senanayake F
Lancet; 1978 May; 1(8073):1101. PubMed ID: 77399
[No Abstract] [Full Text] [Related]
12. Surgery and adjuvant chemotherapy in the treatment of operable breast cancer.
Rossi A; Valagussa P; Bonadonna G
Prog Clin Biol Res; 1977; 12():391-404. PubMed ID: 335401
[No Abstract] [Full Text] [Related]
13. [Breast neoplasms. Progress by means of adjuvant chemotherapy?].
Senn HJ
MMW Munch Med Wochenschr; 1980 Jan; 122(1):10-5. PubMed ID: 6767909
[No Abstract] [Full Text] [Related]
14. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant combination chemotherapy for operable breast cancer. Trials in progress at the Istituto Nazionale Tumori of Milan.
Bonadonna G; Rossi A; Tancini G; Bajetta E; Marchini S; Brambilla C; Tesoro Tess JD; Valagussa P; Banfi A; Veronesi U
Cancer Treat Rep; 1981; 65 Suppl 1():61-5. PubMed ID: 7034930
[TBL] [Abstract][Full Text] [Related]
18. [Preliminary results of a continuous study protocol with adjuvant chemotherapy in primary operable breast carcinoma].
Cavalli F; Jungi F; Alberto P; Martz G; Brunner KW
Haematol Blood Transfus; 1978; 22():61-6. PubMed ID: 374200
[No Abstract] [Full Text] [Related]
19. Adjuvant chemotherapy with four drugs for stage 2 breast cancer.
Wheeler TK; Edelstyn GA; Bates TS; Brinkley D; Evans RG; Kitchen G; MacRae KD; Nicol NT; Spittle M; Wheeler TK
Eur J Cancer (1965); 1980; Suppl 1():161-3. PubMed ID: 7032926
[No Abstract] [Full Text] [Related]
20. [CMF (cyclophosphamide, methotrexate, ftorafur) chemotherapy in advanced breast cancer].
Gottwald G; Szakolczai I
Orv Hetil; 1983 Jan; 124(2):79-84. PubMed ID: 6687491
[No Abstract] [Full Text] [Related]
[Next] [New Search]
